SWOG

Last updated

SWOG (formerly the Southwest Oncology Group) is a National Cancer Institute (NCI) supported organization that conducts clinical trials in adult cancers.

Contents

Comprising more than 4,000 cancer researchers at more than 650 institutions across the United States and Canada, it is one of the largest of the NCI's clinical trial cooperative groups. Member institutions include 24 of the NCI-designated cancer centers, many university medical centers, private institutions, and Community Clinical Oncology Programs.

SWOG is headquartered at the Oregon Health & Science University in Portland, with an operations office in San Antonio, Texas and a statistical center in Seattle, Washington.

SWOG - Leading cancer research. Together. SWOG logo.gif
SWOG - Leading cancer research. Together.

SWOG was created by the NCI in 1956 as the Southwest Cancer Chemotherapy Study Group (SWCCSG) and was headquartered in Houston, Texas. Its primary purpose was to study leukemia, a cancer of the blood which primarily affects children. Then in 1958, the NCI directed the SWCCSG to include the study of adult cancers, and separate administrative divisions were created for pediatric and adult cancers. The group's name was eventually changed to Southwest Oncology Group to reflect its new mission. Although in its early decades most SWOG member institutions were located in the Southwestern United States, the group spread to include members all over the United States and Canada. In 2010, in recognition of this national scope, the group dropped the regional qualifier from its name and adopted the acronym, SWOG, as its official name.

Quality Assurance

SWOG has all of its protocol-driven cases reviewed at the Quality Assurance Review Center (QARC). As mandated by the National Cancer Institute (NCI), every radiotherapy (RT) department participating in a SWOG study submits their data to QARC for review. QARC is located in Lincoln, Rhode Island and reviews thousands of RT cases per year. The center was founded in 1977 as a not-for-profit health care organization designed to provide quality assurance for CALGB studies. Radiotherapy data from around one-thousand hospitals in both the United States and abroad is reviewed and archived at QARC.

Another center for quality assurance is the Radiological Physics Center (RPC) in Houston, Texas. The primary responsibility of the RPC is to assure the National Cancer Institute (NCI) and its cooperative groups like SWOG that all participating institutions are following the basic guidelines regarding the physics-related aspects of radiotherapy. Established in 1968, the RPC has consistently received funding from the NCI in order to perform the aforementioned mission.

Related Research Articles

A radiation therapist, therapeutic radiographer or radiotherapist is an allied health professional who works in the field of radiation oncology. Radiation therapists plan and administer radiation treatments to cancer patients in most Western countries including the United Kingdom, Australia, most European countries, and Canada, where the minimum education requirement is often a baccalaureate degree or postgraduate degrees in radiation therapy. Radiation therapists can also prescribe medications and radiation, interpret tests results, perform follow ups, reviews, and provide consultations to cancer patients in the United Kingdom and Ontario, Canada . In the United States, radiation therapists have a lower educational requirement and often require postgraduate education and certification in order to plan treatments.

<span class="mw-page-title-main">Proton therapy</span> Medical Procedure

In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.

The Children's Oncology Group (COG), a clinical trials group supported by the National Cancer Institute (NCI), is the world's largest organization devoted exclusively to pediatric cancer research. The COG conducts a spectrum of clinical research and translational research trials for infants, children, adolescents, and young adults with cancer.

The National Wilms Tumor Study Group (NWTS) is a cancer research cooperative group in the United States formed to study a type of kidney tumor that affects children called Wilms' tumor. In 2001, NWTS merged with several other pediatric oncology cooperative groups to create the Children's Oncology Group (COG). However, the NWTS is still active in name today completing follow-up of the late effects of treatment for patients previously enrolled in its trials. The acronym NWTS is pronounced like the word "nitwits".

The Pediatric Oncology Group (POG) was a U.S. and Canadian clinical trial cooperative group created with the mission of studying childhood cancers. It was formed by the merger of the pediatric divisions of two other cooperative groups, the Southwest Oncology Group (SWOG) and the CALGB. In 2000, POG merged with several other pediatric cooperative groups to form the Children's Oncology Group (COG). This merger has seen its fair share of problems, especially with regard to integrating the various databases associated with each individual cooperative group. One such initiative to consolidate these databases involves caBIG or the cancer Biomedical Informatics Grid, which is guided and supported by the National Cancer Institute (NCI) in Bethesda, Maryland.

The Intergroup Rhabdomyosarcoma Study Group (IRS) was a U.S. and Canadian clinical trial cooperative group created with the mission of studying childhood cancers. In 2000, IRS merged with several other pediatric cooperative groups to form the Children's Oncology Group (COG). This merger has seen its fair share of problems, especially with regard to integrating the various databases associated with each individual cooperative group. One such initiative to consolidate these databases involves caBIG, or cancer BIG, which is guided and supported by the National Cancer Institute (NCI) in Bethesda, Maryland. They published a report on cancer treatment protocols published by the National Institute of Health in 2001, and a separate report in 2011 on improving outcomes for patients with low-risk embryonal rhabdomyosarcoma.

<span class="mw-page-title-main">Tata Memorial Centre</span> Hospital in Maharashtra, India

The Tata Memorial Center (TMC) is an autonomous grant-in-aid institution administered under the under the Department of Atomic Energy, Government of India. The TMC umbrella includes multiple cancer institutes across the length and breadth of India, providing yeoman service to cancer patients. The largest and the central hub of these hospitals is the Tata Memorial Hospital (TMH) situated in Parel, Mumbai, is India's oldest and largest cancer institute.

<span class="mw-page-title-main">European Organisation for Research and Treatment of Cancer</span> International nonprofit organization

The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.

<span class="mw-page-title-main">Royal College of Radiologists</span> Professional association of clinical oncologist and radiologist

The Royal College of Radiologists (RCR) is the professional body responsible for the specialties of clinical oncology and clinical radiology throughout the United Kingdom. Its role is to advance the science and practice of radiology and oncology, further public education, and set appropriate professional standards of practice. The college sets and monitors the educational curriculum for those training to enter the profession, and administers the Fellowship of the Royal College of Radiologists exams. It is a registered charity in the United Kingdom (no. 211540).

The Imaging and Radiation Oncology Core (IROC) is a center for the evaluation of data produced by clinical trials funded by the National Cancer Institute, as part of the National Clinical Trials Network "to provide integrated radiation oncology and diagnostic imaging quality control programs... thereby assuring high quality data for clinical trials designed to improve the clinical outcomes for cancer patients worldwide."

<span class="mw-page-title-main">Cancer and Leukemia Group B</span> U.S. research cooperative group

Cancer and Leukemia Group B is a cancer research cooperative group in the United States.

<i>Clinical Lung Cancer</i> Academic journal

Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999.

The Cancer Trials Support Unit(CTSU) is a service of the National Cancer Institute (NCI) in the United States.

Robert E. Wittes was Physician-in-Chief of Memorial Sloan-Kettering Cancer Center, from 2002 until December 31, 2012. Prior to his appointment at MSKCC, he was Deputy Director for Extramural Sciences and Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, where he oversaw NCI's extramural clinical and basic research programs, including the evaluation of new therapeutics, diagnostics, and translational research. Wittes is a fellow of the American College of Physicians, a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Federation for Medical Research. In addition to his institutional affiliations, Dr. Wittes has served as editor-in-chief of the Journal of the National Cancer Institute and Oncology. He has served on the editorial boards of Clinical Cancer Research, Current Opinion in Oncology, The American Journal of Clinical Oncology; Cancer Investigation, and The International Journal of Radiation Oncology-Biology & Physics, among others.

Minesh P. Mehta is an American radiation oncologist and physician-scientist of Indian origin and Ugandan birth. He is currently deputy director and chief of radiation oncology at Miami Cancer Institute at Baptist Health South Florida.

Christopher M. Nutting is a British Professor of Clinical Oncology and medical consultant, specializing in head and neck cancers, who has helped develop Intensity-Modulated Radiotherapy (IMRT), an advanced form of Radiation therapy.

Gibbs Cancer Center & Research Institute is a cancer treatment and research facility in Upstate South Carolina. Gibbs Cancer Center is associated with the NCI Community Cancer Centers Program and the Medical University of South Carolina. Gibbs has several locations across the upstate of South Carolina, including Comprehensive Cancer Centers at both Spartanburg Medical Center and Pelham Medical Center. Additional infusion facilities are located in Gaffney, Union, Mary Black and North Grove.

Joaquín Gómez Mira is a scientist and physician specialized in radiation oncology. Born and raised in Spain, he completed his studies and developed his career in the United States, where he moved in 1967. He is a member of the American Society of Clinical Oncology, and a Fellow and appointed councilor of the American College of Radiology. His work, achievements and lectures in the field of radiation oncology are held in high regard.

Deborah Watkins Bruner is an American researcher, clinical trialist, and academic. She is the senior vice president for research at Emory University. Her research focus is on patient reported outcomes, symptom management across cancer sites, sexuality after cancer treatment, and effectiveness of radiotherapy modalities. Bruner's research has been continually funding since 1998, with total funding of her research exceeding $180 million. She is ranked among the top five percent of all National Institutes of Health-funded investigators worldwide since 2012, according to the Blue Ridge Institute for Medical Research.

Patrick J. Loehrer is an American oncologist who is Indiana University Distinguished Professor, Joseph W. and Jackie J. Cusick Professor in Oncology, Professor of medicine, Indiana University School of Medicine; Director emeritus, Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

References